Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 12, 2019

ProQR doses first patient in Aurora trial of retinal disease therapy

ProQR Therapeutics has dosed the first patient in a Phase I/II Aurora clinical trial to evaluate QR-1123 in patients with autosomal dominant retinitis pigmentosa (adRP).

ProQR Therapeutics has dosed the first patient in a Phase I/II Aurora clinical trial to evaluate QR-1123 in patients with autosomal dominant retinitis pigmentosa (adRP).

The first-in-human study, Aurora (PQ-1123-001), will initially include up to 35 adults with adRP due to the P23H mutation in the rhodopsin (RHO) gene.

Single-dose escalation (open-label) groups and multiple-dose escalation (double-masked) groups in the trial will receive intravitreal injections of QR-1123 or sham procedures in one eye.

The trial’s objective is to evaluate the safety and tolerability of QR-1123.

ProQR Therapeutics Research & Development executive vice-president David Rodman said: “QR-1123 aims to block expression of the toxic mutated rhodopsin protein in the retina thereby targeting the underlying cause of the vision loss associated with adRP due to the P23H mutation.

“We are excited to have started a clinical trial for the third RNA therapy in our inherited retinal disease pipeline.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

ProQR will also assess efficacy as measured by improvement of visual function and retinal structure through ophthalmic endpoints such as visual acuity, visual field and optical coherence tomography.

The company plans to perform the trial at expert sites in North America and expects initial data in 2021.

QR-1123 was in-licensed from Ionis Pharmaceuticals last year and will be administered through intravitreal injections in the eye.

The therapy is a first-in-class investigational RNA-based oligonucleotide that has been designed to potentially treat adRP.

It specifically binds the mutated RHO mRNA and aims to inhibit the formation of the mutated toxic version of the rhodopsin protein.

QR-1123 secured Orphan Drug designation in the US and Fast Track designation from the FDA.

adRP, a severe and rare genetic disease, causes progressive problems in night vision during childhood and leads to visual field loss. It frequently results in blindness in mid-adulthood.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU